Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K

Mitochondrial targets in IDH1-mutated cholangiocarcinoma

Camila Carvalho1, Fulei Wuchu2,3, Nicole Peterson1

  • 1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Hepatology Communications
|February 27, 2026
PubMed

Insights

Cholangiocarcinoma with IDH1 mutations shows unique mitochondrial vulnerabilities. Targeting mitochondrial metabolism, including the TCA cycle and glutamine pathways, offers a promising therapeutic strategy for this challenging cancer.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Mitochondrial Biology

Background:

  • Cholangiocarcinoma (CCA) is a difficult-to-treat biliary tract cancer with poor survival rates.
  • Recent research indicates IDH1-mutated CCA possesses distinct mitochondrial vulnerabilities.
  • Current targeted therapies for CCA have limitations.

Purpose of the Study:

  • To explore the therapeutic potential of targeting mitochondrial metabolism in IDH1-mutated Cholangiocarcinoma.
  • To review preclinical evidence for inhibiting key metabolic pathways in IDH1-mutated CCA.
  • To emphasize the need for integrating mitochondrial-targeted therapies into clinical trials.

Main Methods:

  • Review of preclinical data on mitochondrial metabolism in IDH1-mutated CCA.
  • Analysis of studies investigating the tricarboxylic acid (TCA) cycle.
  • Examination of research on glutamine metabolism inhibition.
  • Exploration of potential combination therapies targeting mitochondria.

Main Results:

  • IDH1-mutated CCA exhibits specific vulnerabilities in mitochondrial function.
  • Inhibition of the TCA cycle shows preclinical promise.
  • Targeting glutamine metabolism is a viable strategy.
  • Combination approaches may enhance therapeutic efficacy.

Conclusions:

  • Mitochondrial metabolism represents a critical therapeutic target in IDH1-mutated CCA.
  • Preclinical evidence supports targeting TCA cycle and glutamine pathways.
  • Future clinical investigations should incorporate mitochondrial-targeted strategies.
Keywords:
cholangiocarcinomaivosidenibmutant isocitrate dehydrogenasetargeted therapy

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K
Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues08:36

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues

Published on: May 26, 2018

12.3K

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K